NCT06280495 2026-04-20
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Phase 2/3 Recruiting
Clinical Trials
12 trialsNCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT05462613 2024-12-20
REPROGRAM-02
Centre Hospitalier Universitaire de Besancon
Phase 2/3 Recruiting
NCT05807893 2024-11-13
SUPER BRAIN
Sun Yat-sen University
Phase 2/3 Completed
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT00651456 2023-03-13
MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2/3 Completed
NCT04138992 2020-06-30
A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer
Air Force Military Medical University, China
Phase 2/3 Unknown
NCT00952029 2020-03-30
Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT03686254 2018-09-26
The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT02959749 2018-02-14
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Qingdao Central Hospital
Phase 2/3 Completed
NCT00930891 2016-03-10
CPC
Intergroupe Francophone de Cancerologie Thoracique
Phase 2/3 Completed
NCT01426880 2016-02-15
GeparSixto
GBG Forschungs GmbH
Phase 2/3 Completed